دورية أكاديمية
أعرض في EDS

A systematic review of the utility of amino acid PET in assessing treatment response to bevacizumab in recurrent high-grade glioma.

التفاصيل البيبلوغرافية
العنوان: A systematic review of the utility of amino acid PET in assessing treatment response to bevacizumab in recurrent high-grade glioma.
المؤلفون: Hughes KL; Department of Neurosurgery, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA., O'Neal CM; Department of Neurosurgery, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA., Andrews BJ; Department of Neurosurgery, University of North Carolina, Chapel Hill, North Carolina, USA., Westrup AM; Department of Neurosurgery, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA., Battiste JD; Department of Neurosurgery, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA., Glenn CA; Department of Neurosurgery, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.
المصدر: Neuro-oncology advances [Neurooncol Adv] 2021 Mar 07; Vol. 3 (1), pp. vdab003. Date of Electronic Publication: 2021 Mar 07 (Print Publication: 2021).
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: Oxford University Press Country of Publication: England NLM ID: 101755003 Publication Model: eCollection Cited Medium: Internet ISSN: 2632-2498 (Electronic) Linking ISSN: 26322498 NLM ISO Abbreviation: Neurooncol Adv Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: [Oxford] : Oxford University Press, [2019]-
مستخلص: Background: Currently, bevacizumab (BEV), an antiangiogenic agent, is used as an adjunctive therapy to re-irradiation and surgery in patients with recurrent high-grade gliomas (rHGG). BEV has shown to decrease enhancement on MRI, but it is often unclear if these changes are due to tumor response to BEV or treatment-induced changes in the blood brain barrier. Preliminary studies show that amino acid PET can aid in distinguishing these changes on MRI.
Methods: The authors performed a systematic review of PubMed and Embase through July 2020 with the search terms 'bevacizumab' or 'Avastin' and 'recurrent glioma' and 'PET,' yielding 38 papers, with 14 meeting inclusion criteria.
Results: Thirteen out of fourteen studies included in this review used static PET and three studies used dynamic PET to evaluate the use of BEV in rHGG. Six studies used the amino acid tracer [18F]FET, four studies used [11C]MET, and four studies used [18F]FDOPA.
Conclusion: [18F]FET, [11C]MET, and [18F]FDOPA PET in combination with MRI have shown promising results for improving accuracy in diagnosing tumor recurrence, detecting early treatment failure, and distinguishing between tumor progression and treatment-induced changes in patients with rHGG treated with BEV.
(© The Author(s) 2021. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.)
References: Neuroimage Clin. 2016 Dec 18;13:386-394. (PMID: 28116231)
Eur J Nucl Med Mol Imaging. 2014 Jun;41(6):1199-209. (PMID: 24604590)
J Neurooncol. 2017 Apr;132(2):277-286. (PMID: 28102485)
J Nucl Med. 2012 Jul;53(7):1048-57. (PMID: 22645298)
Eur J Nucl Med Mol Imaging. 2019 Mar;46(3):540-557. (PMID: 30519867)
Amino Acids. 2015 Feb;47(2):335-44. (PMID: 25385314)
J Nucl Med. 2013 Aug;54(8):1217-22. (PMID: 23785172)
J Neurooncol. 2017 Jul;133(3):455-467. (PMID: 28527008)
AJR Am J Roentgenol. 2018 Dec;211(6):1342-1347. (PMID: 30332289)
Eur J Nucl Med Mol Imaging. 2013 Jan;40(1):22-33. (PMID: 23053325)
Rev Esp Med Nucl Imagen Mol. 2015 Nov-Dec;34(6):398-9. (PMID: 26092078)
J Clin Oncol. 2010 Apr 10;28(11):1963-72. (PMID: 20231676)
Brain. 2005 Mar;128(Pt 3):678-87. (PMID: 15689365)
J Nucl Med. 2011 Jun;52(6):856-64. (PMID: 21622893)
Contrast Media Mol Imaging. 2018 Dec 2;2018:6828396. (PMID: 30627060)
J Neurooncol. 2013 Jan;111(1):11-8. (PMID: 23086431)
Neurooncol Pract. 2016 Mar;3(1):59-67. (PMID: 31579522)
Expert Rev Anticancer Ther. 2017 May;17(5):395-397. (PMID: 28277832)
Neuro Oncol. 2016 Sep;18(9):1199-208. (PMID: 27106405)
Clin Nucl Med. 2016 Nov;41(11):852-857. (PMID: 27648703)
Lancet Oncol. 2014 Aug;15(9):943-53. (PMID: 25035291)
J Nucl Med. 2001 Mar;42(3):432-45. (PMID: 11337520)
Curr Oncol Rep. 2011 Feb;13(1):50-6. (PMID: 21086192)
J Neurooncol. 2010 Sep;99(2):217-25. (PMID: 20091333)
Nat Med. 2001 Sep;7(9):987-9. (PMID: 11533692)
Sci Rep. 2019 Feb 27;9(1):2878. (PMID: 30814660)
Neuro Oncol. 2012 Aug;14(8):1079-89. (PMID: 22711609)
J Nucl Med. 2014 Oct;55(10):1611-6. (PMID: 25125481)
Clin Nucl Med. 2019 Mar;44(3):186-193. (PMID: 30562194)
J Clin Oncol. 1990 Jul;8(7):1277-80. (PMID: 2358840)
Eur J Nucl Med Mol Imaging. 2018 Dec;45(13):2377-2386. (PMID: 29982845)
Clin Cancer Res. 2014 Jul 1;20(13):3550-9. (PMID: 24687922)
Eur J Nucl Med Mol Imaging. 2019 Mar;46(3):558-568. (PMID: 30612162)
Eur J Nucl Med Mol Imaging. 2017 Aug;44(8):1285-1295. (PMID: 28258444)
Neuro Oncol. 2011 Mar;13(3):353-61. (PMID: 21310734)
N Engl J Med. 2005 Mar 10;352(10):987-96. (PMID: 15758009)
Neuro Oncol. 2019 Dec 17;21(12):1595-1606. (PMID: 31618420)
فهرسة مساهمة: Keywords: amino acid PET; bevacizumab; pseudoresponse; recurrent glioma
تواريخ الأحداث: Date Created: 20210819 Latest Revision: 20210820
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC8369430
DOI: 10.1093/noajnl/vdab003
PMID: 34409294
قاعدة البيانات: MEDLINE
الوصف
تدمد:2632-2498
DOI:10.1093/noajnl/vdab003